US5445941A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for screening anti-osteoporosis agents
Assignee: Eli Lilly and Co
•
Filing: 1993-06-21
•
Granted: 1995-08-29
•
Expires: 2013-06-21
Abstract
Abstract The present invention relates to methods for the identification of therapeutic agents for the treatment of osteoporosis and serum lipid lowering agents. The invention relates to isolating cloning, and using nucleic acids from the promoter regions of transforming growth factor β genes comprising novel regulatory elements designated "raloxifene responsive elements". The invention also encompasses eukaryotic cells containing such raloxifene responsive elements operably linked to reporter genes such that the raloxifene responsive elements modulate the transcription of the reporter genes. The invention provides methods for identifying anti-osteoporosis agents that induce transcription of genes operably linked to such raloxifene responsive elements without inducing deleterious or undesirable side effects associated with current anti-osteoporosis therapy regimens.
Inventors
- 👤 Na N. Yang
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 03:42
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K31/435; A61K31/44; A61K31/445; C; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/475; C07K14/495; C07K14/705; C07K14/72; C07K14/721; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12Q; C12Q1/00; C12Q1/68; C12Q1/6897; C12N2830/00; C12N2830/001; C12N2830/002; C12N2830/80; C12N2830/85
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
161 words
A method of screening a multiplicity of compounds to identify a compound having potential as an anti-osteoporosis agent, the method comprising identifying a compound of the multiplicity that is capable of inducing transcription from a raloxifene responsive element of a mammalian promoter, that is not a non-specific transcription inducer, is not capable of inducing transcription from an estrogen-responsive element of a mammalian promoter and that is an anti-estrogenic or non-estrogenic compound, the method comprising the steps of: (a) assaying for the ability of the compound to induce transcription from a raloxifene responsive element of the mammalian promoter; (b) assaying for the inability of the compound to induce transcription from a mammalian promoter not having a raloxifene responsive element; (c) assaying for the inability of the compound to induce transcription from an estrogen responsive mammalian promoter; and (d) assaying for the ability of the compound to inhibit estrogen induction of transcription from an estrogen responsive mammalian promoter in the presence of estrogen.
Claim 2
Independent Claim
161 words
A method of screening a multiplicity of compounds to identify a compound having potential as an anti-osteoporosis agent, the method comprising identifying a compound of the multiplicity that is capable of inducing transcription from a raloxifene responsive element of a mammalian promoter, that is not a non-specific transcription inducer, is not capable of inducing transcription from an estrogen-responsive element of a mammalian promoter and that is an anti-estrogenic or non-estrogenic compound, the method comprising the steps of: (a) assaying for the ability of the compound to induce transcription from a raloxifene responsive element of the mammalian promoter; (b) assaying for the inability of the compound to induce transcription from a mammalian promoter not having a raloxifene responsive element; (c) assaying for the inability of the compound to induce transcription from an estrogen responsive mammalian promoter; and (d) assaying for the ability of the compound to inhibit estrogen induction of transcription from an estrogen responsive mammalian promoter in the presence of estrogen.
Claim 3
Dependent Claim
34 words
A method of claim 1 wherein the assay of subpart (a) comprises the step of determining the ability of the compound to induce expression of a reporter gene operably linked to the mammalian promoter.
Claim 4
Dependent Claim
35 words
A method according to claim 2 wherein the assay of subpart (b) comprises the step of determining the inability of the compound to induce expression of a reporter gene operably linked to the mammalian promoter.
Claim 5
Dependent Claim
35 words
A method according to claim 2 wherein the assay of subpart (c) comprises the step of determining the inability of the compound to induce expression of a reporter gene operably linked to the mammalian promoter.
Claim 6
Dependent Claim
38 words
A method according to claim 2 wherein the assay of subpart (d) comprises the step of determining the ability of the compound to inhibit estrogen-dependent induction of expression of a reporter gene operably linked to the mammalian promoter.
References Cited (Backward Citations)
US4418068A
Cited
GB2210620A
Cited
WO1989012101A1
Cited
WO1991001379A1
Cited
US5183736A
Cited
WO1992000330A1
Cited
WO1992000318A1
Cited
WO1992013063A1
Cited
WO1992013091A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-08-28 | 1999-02-27 | 1999-08-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-08-28 | 2003-02-27 | 2003-08-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-08-28 | 2007-02-27 | 2007-08-29 | $7700.00 | Window Closed / Lapsed |